Clearmind Medicine Inc. announced the successful initiation of a clinical trial site at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa study of CMND-100, an oral drug candidate for Alcohol Use Disorder (AUD). This trial, also being conducted at Yale, Johns Hopkins, and Hadassah Medical Center, aims to evaluate CMND-100’s safety, tolerability, pharmacokinetics, and preliminary efficacy in reducing alcohol cravings and consumption. The addition of TASMC, led by Prof. David Zeltser, strengthens Clearmind’s clinical network and accelerates patient enrollment.
This development is crucial because it expands the scope and potential impact of the CMND-100 trial. Including a prominent Israeli medical center alongside prestigious American institutions provides a more diverse patient population and potentially accelerates the timeline for data collection and analysis. This broader reach could enhance the generalizability of the trial results and contribute valuable insights into the drug’s efficacy across different demographics. Moreover, positive trial results would be a significant step towards addressing the substantial unmet need for effective AUD treatments, given the prevalence and global impact of this disorder.
The Phase I/IIa trial is investigating CMND-100, derived from the molecule 5-methoxy-2-aminoindane (MEAI). Preclinical studies suggest MEAI reduces alcohol cravings. This trial represents a critical step in advancing CMND-100’s clinical development. The successful initiation of multiple sites suggests Clearmind is effectively executing its clinical strategy.
The inclusion of TASMC marks positive momentum for Clearmind. Successful completion of this trial phase could pave the way for larger-scale studies and potentially lead to a new treatment option for AUD, a condition with limited effective therapies. The emerging data from this trial will be essential in determining the future development and potential market positioning of CMND-100.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
